Assessing What Matters to People Affected by Alzheimer’s Disease: A Quantitative Analysis
2023 · Neurology and Therapy · 20 citations
https://doi.org/10.1007/s40120-023-00445-0
A
Ann Hartry
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
62
Papers
1.0K
Citations
17
h-index
26
i10-index
Ann Hartry is an academic researcher from Eli Lilly (United States). The author has contributed to research in topics: Dementia and Cognitive Impairment Research & Schizophrenia research and treatment & Health Systems, Economic Evaluations, Quality of Life. The author has an h-index of 17, co-authored 53 publications.
ORCID: 0000-0001-8649-1311Papers by this author
worksTechnical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease
2023 · Neurology and Therapy · 17 citations
https://doi.org/10.1007/s40120-023-00443-2
Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder
2018 · Journal of Medical Economics · 14 citations
https://doi.org/10.1080/13696998.2018.1484373
Earlier Versus Later Augmentation with an Antipsychotic Medication in Patients with Major Depressive Disorder Demonstrating Inadequate Efficacy in Response to Antidepressants: A Retrospective Analysis of US Claims Data
2018 · Advances in Therapy · 10 citations
https://doi.org/10.1007/s12325-018-0838-2
Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment
2019 · Clinical Therapeutics · 7 citations
https://doi.org/10.1016/j.clinthera.2018.12.005
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat